POS0271 INFLIXIMAB FOR PARENCHYMAL NEURO-BEHÇET’S SYNDROME: A META-ANALYSIS

英夫利昔单抗 医学 病理 疾病
作者
Wenjie Zheng,Xiao Wang,Yan Liu,Yiyuan Ao,Jinling Wang,J. Liu,Yan Xu
标识
DOI:10.1136/annrheumdis-2024-eular.2748
摘要

Background:

Behçet's syndrome (BS) is a chronic, recurrent systemic vasculitis that can affect multiple systems. Neuro-Behçet's syndrome (NBS), especially parenchymal NBS(p-NBS), results in severe neurological sequelae with poor prognosis, ranging from cognitive changes to paralysis, which remains a challenging clinical issue.

Objectives:

This study aimed to evaluate the efficacy and safety of infliximab (IFX), a type of anti-TNF-α agents, in treating patients with p-NBS and hopefully provide a detailed time analysis for the IFX effect timeline in NBS treatment.

Methods:

We conducted this meta-analysis following the PRISMA guidelines. PubMed, Embase, Cochrane Library and Web of Science were systematically searched using the following logics: Behçet's syndrome (all synonyms) AND Infliximab (all synonyms) AND ('neuro' OR 'neurological' OR 'neurologic), and we also included the data from our institution in this meta-analysis. Therapeutic efficacy was evaluated by the improvement of clinical symptoms and radiological lesions, and clinical improvement was specifically defined as complete remission (CR), partial remission (PR) and no response (NR) [1,2]. We evaluated the efficacy of IFX at 3, 6, and 12 months respectively. The results were presented as forest plots with 95% confidence intervals. Besides, the details of adverse drug reactions were recorded.

Results:

8 studies involving a total of 77 patients were identified to perform the meta-analysis by adding the results from our institution. The pooled efficacy of IFX in treating p-NBS patients were analyzed. Clinical complete remission was achieved in 14.7% (95%CI 0.00-83.5%) of patients at Month 3, 28.7% (95% CI 0.00-86.7%) of patients at Month 6, 54.4% (95%CI 13.9-92.3%) at Month 12. Clinical partial remission was achieved in 97.0% (95%CI 61.9-100%) of patients at Months 3, 89.6% (95%CI 45.9-100%) of patients at Months 6, 100.0% (95%CI 96.0-100%) at Months 12. MRI improvement was achieved in 100.0% (95%CI 89.7-100%) of patients at Month 3, 89.1% (95% CI 26.3-100%) of patients at Month 6, 99.5% (95% CI 96.0-100%) at Month 12. The time-phase analysis indicated that IFX exerted its effect within 3 months and was sustained during the long term. Safety information was reported in 16 patients. Among them, 9% of patients experienced severe adverse events (AEs), no AE-related deaths were reported.

Conclusion:

IFX is an effective treatment option for p-NBS, and the incidence of severe AEs was acceptable. A comprehensive evaluation should be performed after three months of medication to determine the need for adjustments in subsequent therapy. Further well-designed, large-scale RCTs are needed to verify our findings.

REFERENCES:

[1] Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016;95:e3863. [2] Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of neuro-Behçet's disease: A case series and review of the literature. Arthritis Care and Research 2008;59:285-90. (Article).

Acknowledgements:

We thank all the participants and their families.

Disclosure of Interests:

None declared.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
英俊的铭应助qqq采纳,获得10
刚刚
Xw完成签到,获得积分10
1秒前
1秒前
量子星尘发布了新的文献求助10
2秒前
ChatGPT发布了新的文献求助10
2秒前
3秒前
3秒前
暴躁的嘉懿完成签到,获得积分10
5秒前
龙傲天完成签到 ,获得积分10
5秒前
hhh发布了新的文献求助10
6秒前
小杨完成签到,获得积分10
8秒前
风华正茂完成签到,获得积分10
9秒前
康康完成签到 ,获得积分10
11秒前
柒z完成签到,获得积分10
13秒前
赘婿应助momo采纳,获得10
17秒前
油点小鳄完成签到,获得积分20
20秒前
21秒前
21秒前
桐桐应助wish采纳,获得10
22秒前
23秒前
桐桐应助百十余采纳,获得10
26秒前
义气如萱发布了新的文献求助10
26秒前
26秒前
27秒前
小二郎应助KM比比采纳,获得10
28秒前
不能吃了发布了新的文献求助10
28秒前
李健的粉丝团团长应助LJJ采纳,获得10
29秒前
30秒前
31秒前
体贴绝音发布了新的文献求助10
31秒前
32秒前
丘比特应助sakegeda采纳,获得10
34秒前
35秒前
wish发布了新的文献求助10
35秒前
不能吃了完成签到,获得积分10
36秒前
36秒前
37秒前
39秒前
好滴捏发布了新的文献求助10
41秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989334
求助须知:如何正确求助?哪些是违规求助? 3531428
关于积分的说明 11253936
捐赠科研通 3270119
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173